Penny Stock Up on Birth Control Buzz

Cantor Fitzgerald's price target is more than double EVFM's price

Digital Content Manager
Dec 17, 2018 at 10:51 AM
facebook twitter linkedin

Successful late-stage results for its experimental birth control, Amphora, have Evofem Biosciences Inc (NASDAQ:EVFM) stock up in early trading. If approved by regulators, the gel-based, hormone-free birth control would be the first of its kind -- news that has EVFM shares up nearly 20% to trade at $4.24. The stock earlier peaked at $4.90 -- the highest it's been since early September.

Analysts have hope for the drug company, too. Roth Capital Partners said today's data "pave(s) the way for Amphora's disruption of the contraception market." Meanwhile, Cantor Fitzgerald waxed optimistic on Evofem Biosciences' data, with an "overweight" rating and $9 price target -- more than double the stock's current price. That echoes the high hopes of other analysts, as the consensus 12-month price target sits at $10.40, and all five analysts following EVFM give it a "buy" or better rating. 

Even with today's bull gap, EVFM is down more than 60% year-to-date. The stock has more than doubled since its Aug. 2 low of $1.79, but rebound attempts have stalled just below the $5 area, where the shares were trading before a May bear gap. However, today's rally has the stock on pace to break north of a recent ceiling at the $4 level. 


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners